Menu Search
Equities

Renalytix PLC

2O9A:FRA

Renalytix PLC

Actions
  • Price (EUR)0.131
  • Today's Change0.00 / 0.00%
  • Shares traded1.43k
  • 1 Year change-85.36%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

  • Revenue in USD (TTM)2.29m
  • Net income in USD-33.46m
  • Incorporated2018
  • Employees102.00
  • Location
    Renalytix PLCFinsgate, 5-7 Cranwood StreetLONDON EC1V 9EEUnited KingdomGBR
  • Phone+44 292 071 0570
  • Websitehttps://renalytix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.